Blog

Alper Topal: The Keynote 921 study failed for CRPC

Alper Topal/researchgate.net

Mar 18, 2025, 12:35

Alper Topal: The Keynote 921 study failed for CRPC

Alper Topal, Medical Onoclogist at Gülhane Training and Research Hospital, shared a paper Daniel P. Petrylak and colleagues authored on X:

“The Keynote 921 study failed for CRPC.

mPFS was 8.6 months in the pembro arm compared to 8.3 months in the placebo arm.mOS was 19.6 months in the pembro arm compared to 19 months in the placebo arm. Grade 3≥side effects were more common in the pembro arm.”

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

Authors: Daniel P. Petrylak et al.

Alper Topal

Alper Topal Andrew J. Armstrong Andries M. Bergman cancer Charles Schloss Christian H. Poehlein Daniel P. Petrylak Eric Levesque Ernesto Korbenfeld Gero Kramer Howard Gurney Karim Fizazi Loic Mourey Margitta Retz Maria De Santis Meital Levartovsky Nobuaki Matsubara OncoDaily Oncology Pawel Zalewski Raffaele Ratta Ray Manneh Ray McDermott Russell Pachynski Rustem Gafanov Seok Soo Byun Sergio Bracarda Tilman Todenhofer Winald Gerritsen Xin Tong Li

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology